Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down
Hims & Hers Health (HIMS) reported Q2 2026 adjusted loss of 10 cents per share, worse than the year-ago 17 cents and above the Zacks estimate of a 7-cent loss. Revenue rose 38.2% to $753.2 million, but gross margin fell 1256 bps to 63.8%. Subscribers rose to 2.9 million. Shares fell about 6.8% premarket.
How this was made
The 30-second read
Why it matters
The key tradable takeaway is the combination of an adjusted EPS miss and a large gross margin contraction, alongside an operating loss swing, even as revenue and subscribers grew.
Market read
Traders are likely to focus on whether gross margin weakness is temporary (mix and spend) or structural, given the operating loss and expense acceleration.
What to watch
The article notes management attributed higher monthly online revenue per subscriber to product mix, which could mean margins normalize if weight-loss uptake scales as expected.
Background
Hims & Hers released Q2 2026 results, including EPS, revenue growth, subscriber metrics, and detailed expense and margin changes.
Ticker impact
Hims & Hers reported Q2 adjusted loss of 10 cents vs a 7-cent consensus loss, with gross margin down 1256 bps to 63.8%.
Further downside risk in the next sessions as traders reprice margin durability and operating leverage.
The article provides concrete Q2 EPS miss, gross margin decline magnitude, and notes the stock is down nearly 6.8% pre-market, indicating immediate market repricing.
Market effects
Margin pressure at a telehealth/consumer health subscription model can raise scrutiny on unit economics across similar DTC healthcare names.
No specific regional shock beyond disclosed US and Rest-of-World revenue mix changes.
Limited, as the disclosure is company-specific and not tied to a broader regulatory or macro event.
Counterpoint
Despite the margin drop, revenue growth and subscriber gains were strong, suggesting the miss may be driven by mix and spend rather than demand collapse.
Key entities
- companyHims & Hers Health, Inc.
Reported Q2 2026 adjusted loss of 10 cents, gross margin down 1256 bps to 63.8%, and pre-market stock decline of nearly 6.8%.
